ClinicalTrials.gg
CompletedNCT01730053Updated Apr 7, 2020Results posted

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

A Phase 3 interventional study of Alirocumab and Rosuvastatin in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 93 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
15th of 43
305 · median 107
Started
2012
with 11 others
Phase 3
20 of 43
none open now
Registered
19th of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 15th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 19th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

To evaluate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab (REGN727/SAR236553) as an add-on therapy to other LMT in patients with hypercholesterolemia at high cardiovascular (CV) risk.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with LDL-C greater than or equal to 70 mg/dL at the screening visit and who are not adequately controlled with a stable daily dose of rosuvastatin, with or without other LMT.

    OR

  2. Patients with screening LDL-C greater than or equal to 100 mg/dL who are not adequately controlled with a stable daily dose of rosuvastatin before the screening visit, with or without other LMT.

Exclusion criteria

Exclusion Criteria:

  1. LDL-C less than 70 mg/dL at the screening visit in patients with history of documented cardiovascular disease (CVD)
  2. LDL-C less than 100 mg/dL at the screening visit in patients without history of documented coronary heart disease (CHD) or non-CHD CVD, but with other risk factors
  3. Homozygous familial hypercholesterolemia (FH) (clinically or previous genotyping)
  4. Recent (within 3 months prior to the screening visit) myocardial infarction (MI), unstable angina leading to hospitalization, percutaneous coronary intervention (PCI), coronary bypass graft surgery (CABG), uncontrolled cardiac arrhythmia, stroke, , carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease
  5. Newly diagnosed (within 3 months prior to randomization visit) or poorly controlled diabetes
  6. Presence of any uncontrolled endocrine disease known to influence serum lipids or lipoproteins

(The inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
305 participants (actual)

Study arms

  • Active comparator
    Rosuvastatin 20 mg

    Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.

    Drug: Rosuvastatin · Drug: Placebo

  • Active comparator
    Ezetimibe 10 mg + Rosuvastatin 10 mg

    Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.

    Drug: Rosuvastatin · Drug: Ezetimibe · Drug: Placebo

  • Experimental
    Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg

    Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.

    Drug: Alirocumab · Drug: Rosuvastatin · Drug: Placebo

  • Active comparator
    Rosuvastatin 40 mg

    Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.

    Drug: Rosuvastatin · Drug: Placebo

  • Active comparator
    Ezetimibe 10 mg + Rosuvastatin 20 mg

    Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.

    Drug: Rosuvastatin · Drug: Ezetimibe · Drug: Placebo

  • Experimental
    Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg

    Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.

    Drug: Alirocumab · Drug: Rosuvastatin · Drug: Placebo

Interventions

  • Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.

    Also known as: REGN727/SAR236553

  • Rosuvastatin over-encapsulated tablets orally.

    Also known as: Crestor

  • Ezetimibe over-encapsulated tablets orally.

    Also known as: Ezetrol

  • DrugPlacebo

    Placebo for alirocumab and ezetimibe.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 24

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 24

  2. Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).

    Time frame: From Baseline to Week 12

  3. Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

    Time frame: From Baseline to Week 12

  4. Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  5. Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).

    Time frame: From Baseline to Week 24

  6. Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  7. Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

    Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).

    Time frame: From Baseline to Week 24

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  9. Percent Change From Baseline in Apo B at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  10. Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  11. Percent Change From Baseline in Total-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  12. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 24

  13. Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

    Time frame: Up to Week 24

  14. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

    Time frame: Up to Week 24

  15. Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

    Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

    Time frame: Up to Week 24

  16. Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  17. Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  18. Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

    Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  19. Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

    Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 24

  20. Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  21. Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  22. Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

    Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  23. Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

07

Results

Posted Oct 28, 2015

Participant flow

The study was conducted at 79 sites in 8 countries. Overall, 672 participants were screened between 24 October 2012 and 27 September 2013, 367 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.

Participant flow — Overall Study
MilestoneRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Started484849535354
Treated484849535354
Completed433438454441
Not completed514118913
Withdrew: Participant moved001000
Withdrew: Physician decision000100
Withdrew: Adverse event263322
Withdrew: Poor compliance to protocol122002
Withdrew: Other than specified265479

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis-16.3 ± 4.1-14.4 ± 4.4-50.6 ± 4.2-15.9 ± 7.1-11.0 ± 7.2-36.3 ± 7.1
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -34.2 · 98.75% CI -49.2 to -19.3
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -36.1 · 98.75% CI -51.5 to -20.7
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg · Mixed Models Analysis · p = =0.0453 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -20.3 · 98.75% CI -45.8 to 5.1
  • Ezetimibe 10 mg + Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg · Mixed Models Analysis · p = =0.0136 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -25.3 · 98.75% CI -50.9 to 0.3
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis-18.3 ± 3.3-20.3 ± 3.6-53.5 ± 3.5-17.0 ± 6.9-16.5 ± 6.9-41.5 ± 6.9
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -35.2 · 98.75% CI -47.4 to -23.0
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -33.2 · 98.75% CI -45.9 to -20.5
  • Rosuvastatin 40 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg · Mixed Models Analysis · p = =0.0131 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -24.5 · 98.75% CI -49.2 to 0.2
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment (ITT analysis).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis-17.1 ± 4.1-17.4 ± 4.2-49.6 ± 4.1-22.1 ± 5.3-19.3 ± 5.4-32.3 ± 5.2
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -35.2 · 98.75% CI -47.4 to -17.9
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -32.2 · 98.75% CI -47 to -17.5
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first) (on-treatment analysis).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis-17.2 ± 3.6-20.3 ± 3.8-52.6 ± 3.6-22.9 ± 5.2-21.8 ± 5.2-35.1 ± 5.2
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -35.3 · 98.75% CI -48.2 to -22.5
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -32.3 · 98.75% CI -45.6 to -19.0
SecondaryPercent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis-7.3 ± 3.0-9.7 ± 3.1-36.5 ± 3.1-9.8 ± 4.1-11.2 ± 4.3-28.3 ± 4.3
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -29.2 · 98.75% CI -40.1 to -18.3
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -26.8 · 98.75% CI -37.9 to -15.7
SecondaryPercent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (ie. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis-8.8 ± 2.6-11.2 ± 2.7-39.5 ± 2.6-12.7 ± 4.0-12.6 ± 4.1-30.4 ± 4.2
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -30.7 · 98.75% CI -40.1 to -21.3
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -28.3 · 98.75% CI -38.0 to -18.7
SecondaryPercent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis-11.3 ± 3.4-13.4 ± 3.7-42.7 ± 3.5-11.2 ± 5.1-12.9 ± 5.2-31.4 ± 5.2
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -31.4 · 98.75% CI -43.9 to -18.9
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -29.3 · 98.75% CI -42.1 to -16.4
SecondaryPercent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis

Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first).

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis-12.9 ± 2.8-17.5 ± 3.1-45.7 ± 2.9-14.9 ± 4.2-18.2 ± 4.2-35.6 ± 4.3
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -32.8 · 98.75% CI -43.2 to -22.4
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -28.2 · 98.75% CI -39.1 to -17.3
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis-8.3 ± 2.4-8.7 ± 2.6-28.9 ± 2.5-8.5 ± 3.6-12.4 ± 3.6-20.6 ± 3.6
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -20.6 · 98.75% CI -29.4 to -11.8
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -20.3 · 98.75% CI -29.3 to -11.2
SecondaryPercent Change From Baseline in Apo B at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis-8.1 ± 3.2-12.1 ± 3.3-36.1 ± 3.2-13.7 ± 3.3-14.3 ± 3.3-29.0 ± 3.3
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -28.1 · 98.75% CI -39.7 to -16.5
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -24.0 · 98.75% CI -35.7 to -12.3
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis-11.7 ± 3.5-16.3 ± 3.6-41.2 ± 3.5-18.0 ± 3.6-18.7 ± 3.7-29.8 ± 3.6
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -29.5 · 98.75% CI -42.1 to -16.9
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -24.9 · 98.75% CI -37.7 to -12.2
SecondaryPercent Change From Baseline in Total-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis-8.9 ± 2.6-11.8 ± 2.7-29.0 ± 2.6-13.8 ± 2.8-13.9 ± 2.8-19.4 ± 2.7
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -20.1 · 98.75% CI -29.4 to -10.7
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Mixed Models Analysis · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Ls mean difference: -17.2 · 98.75% CI -26.7 to -7.7
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
percentage of participantsRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis45.057.284.940.152.266.7
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 12.4 · 98.75% CI 2.6 to 59.5
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = =0.0007 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 8.4 · 98.75% CI 1.8 to 40.5
SecondaryPercentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis47.060.586.441.354.870.4
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 15.6 · 98.75% CI 2.58 to 88.2
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = =0.001 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 9.9 · 98.75% CI 1.7 to 56.7
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to week 24 regardless of status on- or off-treatment were included in the imputation model (ITT analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
percentage of participantsRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis31.343.177.829.943.660.1
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 18.6 · 98.75% CI 3.6 to 96.2
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 11.6 · 98.75% CI 2.5 to 53.1
SecondaryPercentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis

Calculated LDL-C values were obtained from Friedewald formula. Adjusted percentages at Week 24 were obtained from a multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 i.e. up to 21 days after last injection or 3 days after the last capsule \[whatever rosuvastatin or ezetimibe\], whichever came first (on-treatment analysis).

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
percentage of participantsRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis34.846.776.530.645.166.1
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 20.3 · 98.75% CI 2.4 to 67.7
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Logistic · p = =0.0002 (Threshold for significance ≤ 0.0125.) · Odds ratio (or): 12.7 · 98.75% CI 2.4 to 67.7
SecondaryPercent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis-4.0 ± 4.3-4.3 ± 4.5-27.9 ± 4.1-5.2 ± 4.8-5.8 ± 4.6-22.7 ± 5.1
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Robust · p = <0.0001 (Threshold for significance ≤ 0.0125.) · Adjusted mean difference: -23.9 · 98.75% CI -38.6 to -9.1
  • Ezetimibe 10 mg + Rosuvastatin 10 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Robust · p = =0.0001 (Threshold for significance ≤ 0.0125.) · Adjusted mean difference: -23.6 · 98.75% CI -39.0 to -8.2
SecondaryPercent Change From Baseline in HDL-C at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis1.7 ± 2.44.0 ± 2.59.1 ± 2.41.5 ± 2.3-1.8 ± 2.37.2 ± 2.3
Statistical analysis
  • Rosuvastatin 20 mg vs Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg · Regression, Robust · p = =0.0311 (Threshold for significance ≤ 0.0125.) · Ls mean difference: 7.4 · 98.75% CI -1.2 to 16.1
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis

Adjusted means and standard errors at Week 24 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis-1.8 ± 4.5-8.3 ± 4.8-11.2 ± 4.6-9.9 ± 4.1-11.1 ± 4.3-8.7 ± 4.5
SecondaryPercent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis

Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis5.4 ± 1.95.0 ± 1.96.7 ± 1.92.9 ± 1.9-0.9 ± 1.96.7 ± 2.0
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis-0.7 ± 3.5-3.9 ± 3.6-20.7 ± 3.53.5 ± 4.27.9 ± 4.1-16.0 ± 4.2
SecondaryPercent Change From Baseline in HDL-C at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis0.7 ± 2.10.2 ± 2.25.9 ± 2.10.6 ± 2.53.1 ± 2.58.0 ± 2.5
SecondaryPercent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis

Adjusted means and standard errors at Week 12 from a multiple imputation approach model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis8.1 ± 4.1-8.2 ± 4.2-14 ± 4.1-2.7 ± 4.0-12.4 ± 4.0-10.1 ± 4.0
SecondaryPercent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
percent changeRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis4.0 ± 1.62.6 ± 1.64.3 ± 1.60.9 ± 1.81.8 ± 1.89.1 ± 1.8

Adverse events

Collected over From Baseline to Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 20 mg—4/48 (8.3%)11/48 (22.9%)
Ezetimibe 10 mg + Rosuvastatin 10 mg—5/48 (10.4%)11/48 (22.9%)
Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg—2/49 (4.1%)11/49 (22.4%)
Rosuvastatin 40 mg—4/53 (7.5%)20/53 (37.7%)
Ezetimibe 10 mg + Rosuvastatin 20 mg—3/53 (5.7%)12/53 (22.6%)
Alirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg—4/54 (7.4%)15/54 (27.8%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
Cardiac failure congestiveCardiac disorders1/480/480/490/530/530/54
Spinal cord infectionInfections and infestations0/481/480/490/530/530/54
ObesityMetabolism and nutrition disorders1/480/480/490/530/530/54
Non-Small cell lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/481/480/490/530/530/54
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/480/480/490/530/530/54
Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/480/480/490/530/530/54
ParaesthesiaNervous system disorders0/481/480/490/530/530/54
SyncopeNervous system disorders0/481/480/490/530/531/54
HaematuriaRenal and urinary disorders0/481/480/490/530/530/54
UrosepsisInfections and infestations0/480/481/490/530/530/54
Most frequent other events
Showing 10 of 11
Most frequent other events
EventRosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mg
NasopharyngitisInfections and infestations1/482/482/496/533/532/54
Upper respiratory tract infectionInfections and infestations3/480/482/496/534/534/54
Pain in extremityMusculoskeletal and connective tissue disorders3/481/482/495/532/530/54
ArthralgiaMusculoskeletal and connective tissue disorders1/480/484/492/531/530/54
MyalgiaMusculoskeletal and connective tissue disorders1/483/480/491/531/534/54
OsteoarthritisMusculoskeletal and connective tissue disorders1/483/481/490/530/530/54
DizzinessNervous system disorders3/481/481/492/531/532/54
NauseaGastrointestinal disorders1/481/483/491/531/530/54
HeadacheNervous system disorders0/481/480/493/530/530/54
DiarrhoeaGastrointestinal disorders0/482/480/493/530/532/54

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75/up to 150 + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mgTotal
Mean61.5 ± 11.1560.4 ± 10.3862.2 ± 11.1160.6 ± 10.1163.1 ± 10.257.9 ± 8.8660.9 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75/up to 150 + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mgTotal
Female152218152226118
Male332631383128187
Low density lipoprotein cholesterol (LDL-C) in mg/dL
Low density lipoprotein cholesterol (LDL-C) in mg/dL(mg/dL)Rosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75/up to 150 + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mgTotal
Mean105.9 ± 36.0102.4 ± 41.9107.3 ± 26.4112.9 ± 43.3119.0 ± 48.0118.3 ± 32.2111.3 ± 39.0
LDL-C in mmol/L
LDL-C in mmol/L(mmol/L)Rosuvastatin 20 mgEzetimibe 10 mg + Rosuvastatin 10 mgAlirocumab 75/up to 150 + Rosuvastatin 10 mgRosuvastatin 40 mgEzetimibe 10 mg + Rosuvastatin 20 mgAlirocumab 75 mg/up to 150 mg + Rosuvastatin 20 mgTotal
Mean2.743 ± 0.9332.653 ± 1.0852.78 ± 0.6842.924 ± 1.1223.082 ± 1.2433.065 ± 0.8342.882 ± 1.009
08

Study locations

93 sites
  • Chandler, Arizona, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Beverly Hills, California, United States
  • Fair Oaks, California, United States
  • Newport Beach, California, United States
  • Northridge, California, United States
  • Sacramento, California, United States
  • Walnut Creek, California, United States
  • Milford, Connecticut, United States
  • Atlantis, Florida, United States
  • Bradenton, Florida, United States
  • Clearwater, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Jacksonville, Florida, United States
  • Lakeland, Florida, United States
  • (2 Locations)
    Miami, Florida, United States
  • Oviedo, Florida, United States
  • Pinellas Park, Florida, United States
  • Port Orange, Florida, United States
  • Sarasota, Florida, United States
  • Tampa, Florida, United States
  • West Palm Beach, Florida, United States
  • Winter Park, Florida, United States
  • Boise, Idaho, United States
  • Morton, Illinois, United States
  • Evansville, Indiana, United States
  • Indianapolis, Indiana, United States
  • Newton, Kansas, United States
  • Overland Park, Kansas, United States
  • Wichita, Kansas, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Auburn, Maine, United States
  • Bethesda, Maryland, United States
  • Edina, Minnesota, United States
  • Rochester, Minnesota, United States
  • Olive Branch, Mississippi, United States
  • Port Gibson, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Butte, Montana, United States
  • Williamsville, New York, United States
  • Cincinnati, Ohio, United States
  • Marion, Ohio, United States
  • Portland, Oregon, United States
  • Warwick, Rhode Island, United States
  • Greer, South Carolina, United States
  • Summerville, South Carolina, United States
  • Kingsport, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Bountiful, Utah, United States
  • Salt Lake City, Utah, United States
  • Herston, Australia
  • New Lambton Heights, Australia
  • Perth, Australia
  • Sherwood, Australia
  • Woolloongabba, Australia
  • Brampton, Ontario, Canada
  • Burlington, Ontario, Canada
  • Etobicoke, Ontario, Canada
  • London, Ontario, Canada
  • Newmarket, Ontario, Canada
  • Thornhill, Ontario, Canada
  • Toronto, Ontario, Canada
  • Chicoutimi, Quebec, Canada
  • Dijon, France
  • Lille, France
  • Bad Oeynhausen, Germany
  • Berlin, Germany
  • Koeln, Germany
  • Regensburg, Germany
  • Ulm, Germany
  • Chieti, Italy
  • Genova, Italy
  • Napoli, Italy
  • Palermo, Italy
  • (2 Locations)
    Roma, Italy
  • Baja California, Mexico
  • Distrito Federal, Mexico
  • (3 Locations)
    Guadalajara, Mexico
  • Monterrey, Mexico
  • Zapopan Jalisco, Mexico
  • (2 Locations)
    Barcelona, Spain
  • Madrid, Spain
  • Santiago, Spain
  • Sevilla, Spain
  • West Bromwich, West Midlands, United Kingdom
  • Chester, United Kingdom
  • Peterborough, United Kingdom
  • Salford, United Kingdom
  • Stevenage, United Kingdom
09

References and documents

Publications

  • Mahmood T, Minnier J, Ito MK, Li QH, Koren A, Kam IW, Fazio S, Shapiro MD. Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. Eur J Prev Cardiol. 2021 Jul 23;28(8):816-822. doi: 10.1177/2047487320915803. Epub 2020 Apr 10. PubMed 34298554 ↗
  • Leiter LA, Tinahones FJ, Karalis DG, Bujas-Bobanovic M, Letierce A, Mandel J, Samuel R, Jones PH. Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials. Diabet Med. 2018 Dec;35(12):1742-1751. doi: 10.1111/dme.13817. Epub 2018 Oct 9. PubMed 30183102 ↗
  • Ray KK, Ginsberg HN, Davidson MH, Pordy R, Bessac L, Minini P, Eckel RH, Cannon CP. Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control. Circulation. 2016 Dec 13;134(24):1931-1943. doi: 10.1161/CIRCULATIONAHA.116.024604. Epub 2016 Oct 24. PubMed 27777279 ↗
  • Farnier M, Jones P, Severance R, Averna M, Steinhagen-Thiessen E, Colhoun HM, Du Y, Hanotin C, Donahue S. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Atherosclerosis. 2016 Jan;244:138-46. doi: 10.1016/j.atherosclerosis.2015.11.010. Epub 2015 Nov 14. PubMed 26638010 ↗
  • Robinson JG, Colhoun HM, Bays HE, Jones PH, Du Y, Hanotin C, Donahue S. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. Clin Cardiol. 2014 Oct;37(10):597-604. doi: 10.1002/clc.22327. Epub 2014 Sep 30. PubMed 25269777 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Apr 2014, 17 months.

Results were first posted in Oct 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2015.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is close to that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2012
First posted
Nov 21, 2012
StartActual
Nov 30, 2012
Primary completionActual
Apr 30, 2014
CompletionActual
May 31, 2014
Results delay requested
Jan 24, 2015
Results first posted
Oct 28, 2015
Last update
Apr 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01730053
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Nov 30, 2012
Primary completion
Apr 30, 2014
Completion
May 31, 2014
Results posted
Oct 28, 2015
Last update
Apr 7, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion